Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial

OBJECTIVES: The aim of this study is to evaluate the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in hospitalized adults with severe SARS-CoV-2 infection. TRIAL DESIGN: This is a prospective, single-center, phase 2, randomized, controlled trial that is blinded to participants and...

Descripción completa

Detalles Bibliográficos
Autores principales: Eckhardt, Christina M., Cummings, Matthew J., Rajagopalan, Kartik N., Borden, Sarah, Bitan, Zachary C., Wolf, Allison, Kantor, Alex, Briese, Thomas, Meyer, Benjamin J., Jacobson, Samuel D., Scotto, Dawn, Mishra, Nischay, Philip, Neena M., Stotler, Brie A., Schwartz, Joseph, Shaz, Beth, Spitalnik, Steven L., Eisenberg, Andrew, Hod, Eldad A., Justman, Jessica, Cheung, Ken, Lipkin, W. Ian, O’Donnell, Max R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7276974/
https://www.ncbi.nlm.nih.gov/pubmed/32513308
http://dx.doi.org/10.1186/s13063-020-04422-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7276974/
https://www.ncbi.nlm.nih.gov/pubmed/32513308
http://dx.doi.org/10.1186/s13063-020-04422-y

Ejemplares similares